Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × INDUSTRY × zanolimumab × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell 1

Interventions

pembrolizumab 24 Cisplatin 24 Gemcitabine 23 Carboplatin 23 Paclitaxel 22 Pemetrexed 13 Docetaxel 13 Drug Therapy 12 Capecitabine 12 Oxaliplatin 11 Bevacizumab 10 Nivolumab 9 Fluorouracil 9 130-nm albumin-bound paclitaxel 8 anlotinib 7 Trastuzumab 7 Temozolomide 5 atezolizumab 4 Rituximab 4 Leucovorin 4 Lenalidomide 4 Irinotecan 4 Ipilimumab 4 Injections 4 Folfox protocol 4 venetoclax 3 pertuzumab 3 osimertinib 3 daratumumab 3 camrelizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00877656 2024-03-18

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

Emergent BioSolutions

Phase 2/3 Completed

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡